摘要
目的:探讨帕利哌酮缓释片治疗首发精神分裂症患者的疗效和安全性。方法:对78例首发精神分裂症患者按入院顺序,以奇偶数法分成帕利哌酮缓释片组和奥氮平组,用简明精神病评定量表(BPRS)和治疗中出现的症状量表(TESS)于治疗前、治疗1周、2周、4周、6周和8周分别进行评定。结果:帕利哌酮缓释片组有效率65.8%,奥氮平组有效率67.5%,两组疗效差异无统计学意义,帕利哌酮缓释片组起效快,不良反应低于奥氮平组,且不良反应轻微。结论:帕利哌酮缓释片与奥氮平对精神分裂症的疗效相当,但起效快且不良反应轻微,依从性更好。
Objective：To explore the efficacy and safety of paliperidone in the treatment of patients with naive senile schizophrenia.Method：78 naive senile schizophrenic patients were randomly assigned to paliperidone or olanzapine treatment for 8 weeks.All patients were evaluated with brief psychiatric rating scale（BPRS） and treatment emergent symptom scale（TESS） before treatment and at the second,fourth、sixth and eighth week.Results：The response rate of paliperidone 65.8% was similar to the rate of olanzapine 67.5%,paliperidone had response earlier and lighter than olanzapine.Conclusion：Paliperidone is effective in treatment of schizophrenia and light side effect.
出处
《临床精神医学杂志》
2011年第4期270-271,共2页
Journal of Clinical Psychiatry
